These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16110059)

  • 21. The PMAC code of marketing practices: time for improvement? Pharmaceutical Manufacturers Association of Canada.
    Desjardins JG
    CMAJ; 1997 Feb; 156(3):363-4. PubMed ID: 9033417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring pharmaceutical company promotions.
    Gillette RD
    Fam Med; 1991 Feb; 23(2):92. PubMed ID: 2037220
    [No Abstract]   [Full Text] [Related]  

  • 23. Hospital companies say ads create understanding of industry's role.
    Rev Fed Am Hosp; 1977 Jun; 10(3):34-5, 38. PubMed ID: 10242908
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmaceutical industry sets new guidelines for marketing to physicians.
    Psychiatr Serv; 2002 Aug; 53(8):1043. PubMed ID: 12180431
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug advertising.
    Med J Aust; 1987 Jun; 146(12):660-1. PubMed ID: 3626920
    [No Abstract]   [Full Text] [Related]  

  • 26. Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines?
    Lexchin J
    CMAJ; 1997 Feb; 156(3):351-6. PubMed ID: 9033415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Letter: Assessment of advertising.
    Wigle WW
    Can Med Assoc J; 1974 Apr; 110(7):759. PubMed ID: 4825144
    [No Abstract]   [Full Text] [Related]  

  • 28. Voluntary self-regulatory codes: what should we expect?
    Lexchin J
    Am J Bioeth; 2003; 3(3):49-50. PubMed ID: 14594491
    [No Abstract]   [Full Text] [Related]  

  • 29. Sin of omission? Pharmaceutical trade group failed to disclose that ad subject was employee.
    Becker C
    Mod Healthc; 2001 Aug; 31(32):5, 8. PubMed ID: 11507868
    [No Abstract]   [Full Text] [Related]  

  • 30. Experiences with GLP/GCP from the pharmaceutical industry's viewpoint.
    Legler UF
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):233-6. PubMed ID: 8361261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmaceutical advertising: from prospectus to marketing.
    Cambronero-Saiz B
    J Epidemiol Community Health; 2007 Apr; 61(4):366. PubMed ID: 17372300
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug promotion: stealth, wealth, and safety.
    Lancet; 1993 Jun; 341(8859):1507-8. PubMed ID: 8099382
    [No Abstract]   [Full Text] [Related]  

  • 33. Advertising standards.
    Drug Ther Bull; 2013 Jul; 51(7):73. PubMed ID: 23842632
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmaceutical promotion.
    Harvey K
    Med J Aust; 1990 Jan; 152(2):57-8. PubMed ID: 2296230
    [No Abstract]   [Full Text] [Related]  

  • 35. [Drug industry's "offers" to health personnel].
    Møller N
    Ugeskr Laeger; 2007 Nov; 169(47):4081. PubMed ID: 18087788
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmaceutical advertising in the Journal.
    Pierach CA
    N Engl J Med; 1992 Dec; 327(23):1688-9. PubMed ID: 1435912
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceutical advertising in the Journal.
    Glass AR
    N Engl J Med; 1992 Dec; 327(23):1688; author reply 1689. PubMed ID: 1435911
    [No Abstract]   [Full Text] [Related]  

  • 38. PAAB: a lesson in self-government.
    Lexchin J
    CMAJ; 1991 Apr; 144(7):844-5. PubMed ID: 2007233
    [No Abstract]   [Full Text] [Related]  

  • 39. "Ethical" drugs.
    Rivin AU
    Pharos Alpha Omega Alpha Honor Med Soc; 1980; 43(2):9-10. PubMed ID: 7384207
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA tells drug and device makers to give balanced picture of risks in ads, labels.
    Kuehn BM
    JAMA; 2009 Jun; 301(24):2541. PubMed ID: 19549965
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.